SCHEMBL17307882

SCHEMBL17307882

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC(C)(C)C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.73
ALDH1A1 P00352 8/20 0.57
PPARG P37231 6/20 0.57
CYP19A1 P11511 5/20 0.57
F7 P08709 4/20 0.57
F3 P13726 4/20 0.57
MAPT P10636 4/20 0.57
PPARD Q03181 4/20 0.57
PPARA Q07869 4/20 0.57
FFAR1 O14842 4/20 0.57
OXER1 Q8TDS5 3/20 0.57
PTGS1 P23219 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP3A4 P08684 3/20 0.57
ALOX15 P16050 3/20 0.57
HSD17B10 Q99714 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
NR1I2 O75469 2/20 0.57
PTGS2 P35354 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17307881 0.98 ACLY (0.77) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL17307879 0.96 ACLY (0.67) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL8006596 0.95 ACLY (0.81) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL3617659 0.88 ACLY (0.77) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL13735034 0.88 ACLY (0.77) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL11863724 0.88 ACLY (0.77) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL3626408 0.88 ACLY (0.77) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL3209530 0.87 ALDH1A1 (0.55) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL14768005 0.87 ALDH1A1 (0.55) ACLYALDH1A1PPARGCYP19A1F7
SCHEMBL3216321 0.87 ALDH1A1 (0.55) ACLYALDH1A1PPARGCYP19A1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170327455-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2017-11-16 US disclosed
US-20170327455-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2017-11-16 US disclosed
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2015-12-03 US disclosed
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease PPARA, PPARG, PPARD ACLY 859/4885ALDH1A1 2441/4885PPARG 2/4885
US-20170327455-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease PPARA, PPARG, PPARD ACLY 859/4885ALDH1A1 2441/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.